Literature DB >> 3114201

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

K Tatsumi, M Fukushima, T Shirasaka, S Fujii.   

Abstract

The inhibitory effects of about 30 compounds, mainly pyrimidine and pyridine derivatives, on 5-fluorouracil degradation catalyzed by dihydrouracil dehydrogenase (DHU dehydrogenase) were investigated. The inhibitory activities of 5-substituted uracil derivatives decreased time-dependently during preincubation with liver extracts, indicating that these compounds are substrates of DHU dehydrogenase. During preincubation, 4,6-dihydroxypyrimidine derivatives were found to be converted to barbituric acid derivatives, which have stronger activities. The inhibitory activity of 2,4-dihydroxypyridine (3-deazauracil), which was stronger than that of uracil, did not change during preincubation, indicating that this compound is not a substrate but is an inhibitor of DHU dehydrogenase, and suggesting that 2,6-dihydroxypyridine (1-deazauracil) could be a potent inhibitor. In the light of these findings, we examined various derivatives of barbituric acid, 2,4-dihydroxypyridine and 2,6-dihydroxypyridine. Among these compounds, 3-cyano-2,6-dihydroxypyridine and 5-chloro-2,4-dihydroxypyridine were the strongest inhibitors with Ki values for DHU dehydrogenase of 2.3 X 10(-7) M and 3.6 X 10(-7) M, respectively.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114201

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  72 in total

1.  Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer.

Authors:  Toru Aoyama; Takaki Yoshikawa; Tsutomu Hayashi; Hiroshi Kuwabara; Yo Mikayama; Takashi Ogata; Haruhiko Cho; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2012-04-21       Impact factor: 7.370

2.  Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.

Authors:  Koji Takeda
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

3.  Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer.

Authors:  Keita Kouzu; Hironori Tsujimoto; Makoto Nishikawa; Manabu Harada; Takao Sugihara; Hiromi Nagata; Shuichi Hiraki; Yoshihisa Yaguchi; Risa Takahata; Shinsuke Nomura; Nozomi Ito; Yusuke Ishibashi; Yujiro Itazaki; Satoshi Tsuchiya; Kazuo Hase; Yoji Kishi; Hideki Ueno
Journal:  Gastric Cancer       Date:  2019-09-25       Impact factor: 7.370

4.  Evaluation of Thymidylate Synthase Expression in Prostate Cancer.

Authors:  Shoichiro Ohta; Shingo Kamoshida; Akito Tashiro; Kei-Ichi O-Ono; Nobuhiro Yasuno; Yasuo Kamakura; Masanori Yasuda
Journal:  Curr Urol       Date:  2015-11-10

5.  Combination therapy of S-1 and CDDP for patients with colorectal cancer.

Authors:  Kazumi Uchida; Kazuhiko Hayashi; Hidekazu Kuramochi; Go Nakajima; Yuji Inoue; Masakazu Yamamoto
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

6.  Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Authors:  Emmanuelle Comets; Kazumasa Ikeda; Paulo Hoff; Pierre Fumoleau; Jantien Wanders; Yusuke Tanigawara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

Review 7.  UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors:  Fumihiro Tanaka
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

8.  Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.

Authors:  Hidehiro Tajima; Tetsuo Ohta; Hirohisa Kitagawa; Koichi Okamoto; Seisho Sakai; Isamu Makino; Jun Kinoshita; Hiroyuki Furukawa; Keishi Nakamura; Hironori Hayashi; Katsunobu Oyama; Masafumi Inokuchi; Hisatoshi Nakagawara; Hideto Fujita; Hiroyuki Takamura; Itasu Ninomiya; Sachio Fushida; Takashi Tani; Takashi Fujimura; Hiroko Ikeda; Seiko Kitamura
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

9.  Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.

Authors:  T Yoshioka; S Kato; M Gamoh; N Chiba; T Suzuki; N Sakayori; S Kato; H Shibata; H Shimodaira; K Otsuka; Y Kakudo; S Takahashi; C Ishioka
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.

Authors:  W Koizumi; N Boku; K Yamaguchi; Y Miyata; A Sawaki; T Kato; Y Toh; I Hyodo; T Nishina; T Furuhata; K Miyashita; Y Okada
Journal:  Ann Oncol       Date:  2009-10-14       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.